Prevent Cancer Foundation welcomes 2024 corporate members dedicated to cancer prevention and early detection
POUR DIFFUSION IMMÉDIATE
Kyra Meister
703-836-1746
kyra.meister@preventcancer.org
Alexandria, Va. – The Prevent Cancer Foundation today announced the 13 companies who are members of their Corporate Membership Program’s 2024 cohort. Launched in 2023, the Foundation’s Corporate Membership Program was created with the goal of accelerating mutual goals and reaffirming a commitment from corporate partners to advancing cancer prevention and early detection.
Program members receive access to Foundation resources and exclusive events—including industry roundtable discussions—creating opportunities to collaborate and exchange ideas throughout the year. Membership supports the Foundation’s work in four key areas: research, education, outreach and advocacy.
“Over the last year, the Prevent Cancer Foundation has had the opportunity to see our Corporate Membership Program not only grow, but flourish.” said Jody Hoyos, CEO of the Prevent Cancer Foundation. “Each of these companies supports our mission just as strongly as we do. By creating meaningful partnerships with experts across the industry, we are able to better guide people of screening age toward better outcomes for their health.”
The 2024 class of corporate members, as of the date of this publication, include:
Or
- Daiichi Sankyo
Argent
- Sciences exactes
- Hologique
Bronze
- AstraZeneca
- Bristol Myers Squibb
- Galaad
- GSK
- Gardien
- Eisaï
- Eli Lilly
- Merck
- Natera
- Novartis
- Sanofi
The Corporate Membership Program is open to companies who support the Foundation’s vision of a world where cancer is preventable, detectable and beatable for all. Those interested in learning more about the program or how to join this community can contact Jennifer Niyangoda, Vice President of Development and Marketing, at jennifer.niyangoda@preventcancer.org.
###
À propos de la Fondation Prévenir le Cancer®
La Fondation Prévenir le Cancer® is the only U.S.-based nonprofit organization solely dedicated to cancer prevention and early detection. Through research, education, outreach and advocacy, we have helped countless people avoid a cancer diagnosis or detect their cancer early enough to be successfully treated. We are driven by a vision of a world where cancer is preventable, detectable and beatable for all.
La Fondation se mobilise pour relever le défi de réduire les décès par cancer de 40% d'ici 2035. Pour y parvenir, nous nous engageons à investir $20 millions dans des technologies innovantes pour détecter le cancer à un stade précoce et faire progresser le dépistage multi-cancer, $10 millions pour étendre le dépistage du cancer et la vaccination. l'accès à des communautés médicalement mal desservies et $10 millions pour informer le public sur les options de dépistage et de vaccination.
Pour plus d'informations, s'il vous plaît visitez www.preventcancer.org.